Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy.

Sabbatini P, Mooney D, Iasonos A, Thaler H, Aghajanian C, Hensley M, Konner J, Spriggs D, Abu-Rustum NR, Dupont J.

Int J Gynecol Cancer. 2007 May-Jun;17(3):589-94. Epub 2007 Feb 9.

PMID:
17300679
2.

CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan.

Gossner G, Coleman RL, Mutch DG, Horowitz NS, Rader JS, Gibb RK, Powell MA, Herzog TJ.

Gynecol Oncol. 2006 Oct;103(1):212-8. Epub 2006 May 3.

PMID:
16677696
3.

Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma.

Fedders M, Hartmann M, Schneider A, Kath R, Camara O, Oelschläger H.

J Cancer Res Clin Oncol. 2007 Sep;133(9):619-25. Epub 2007 Apr 26. Erratum in: J Cancer Res Clin Oncol. 2007 Dec;133(12):1025.

PMID:
17458562
4.
5.

A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.

Rose PG, Smrekar M, Haba P, Fusco N, Rodriguez M.

Am J Clin Oncol. 2008 Oct;31(5):476-80. doi: 10.1097/COC.0b013e31816a6221.

PMID:
18838885
6.

A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma.

Rose PG, Smrekar M, Haba P, Visser C, Beeler JF.

Gynecol Oncol. 2005 Dec;99(3):714-9. Epub 2005 Aug 19.

PMID:
16112177
7.

Quality of life evaluations in patients with ovarian cancer during chemotherapy treatment.

Le T, Leis A, Pahwa P, Wright K, Ali K, Reeder B, Hopkins L, Fung MF.

Gynecol Oncol. 2004 Mar;92(3):839-44.

PMID:
14984950
8.

A phase I study of liposomal doxorubicin (Doxil) with topotecan.

Ryan CW, Fleming GF, Janisch L, Ratain MJ.

Am J Clin Oncol. 2000 Jun;23(3):297-300.

PMID:
10857898
9.
10.

A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group.

Pignata S, Scambia G, Pisano C, Breda E, Di Maio M, Greggi S, Ferrandina G, Lorusso D, Zagonel V, Febbraro A, Riva N, De Rosa V, Gallo C, Perrone F; Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies Group.

Br J Cancer. 2007 Jun 4;96(11):1639-43. Epub 2007 May 8.

11.

A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer.

Vecchione F, Fruscio R, Dell'Anna T, Garbi A, Garcia Parra R, Corso S, Lissoni AA.

Int J Gynecol Cancer. 2007 Mar-Apr;17(2):367-72.

PMID:
17362314
12.

Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.

Pisano C, Greggi S, Tambaro R, Losito S, Iodice F, Di Maio M, Ferrari E, Falanga M, Formato R, Iaffaioli VR, Pignata S.

Anticancer Res. 2005 Sep-Oct;25(5):3501-5.

13.

Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study.

Kang H, Kim TJ, Lee YY, Choi CH, Lee JW, Bae DS, Kim BG.

Gynecol Oncol. 2009 Aug;114(2):210-4. doi: 10.1016/j.ygyno.2009.04.016. Epub 2009 May 14.

PMID:
19446320
15.

Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer.

Rapoport BL, Vorobiof DA, Slabber C, Alberts AS, Hlophe HS, Mohammed C.

Int J Gynecol Cancer. 2009 Aug;19(6):1137-41. doi: 10.1111/IGC.0b013e3181a8b938.

PMID:
19820382
16.

Topotecan and liposomal doxorubicin in recurrent ovarian cancer: is sequence important?

Dupont J, Aghajanian C, Andrea G, Lovegren M, Chuai S, Venkatraman E, Hensley M, Anderson S, Spriggs D, Sabbatini P.

Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:68-73.

PMID:
16515570
17.

Workshop: options for therapy in ovarian cancer.

Herzog TJ, Holloway RW, Stuart GC.

Gynecol Oncol. 2003 Sep;90(3 Pt 2):S45-50. Review.

PMID:
13129496
18.

Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors.

Wagner S, Peters O, Fels C, Janssen G, Liebeskind AK, Sauerbrey A, Suttorp M, Hau P, Wolff JE.

J Neurooncol. 2008 Jan;86(2):175-81. Epub 2007 Jul 20.

PMID:
17641821
19.

Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study.

Koensgen D, Stengel D, Belau A, Klare P, Oskay-Oezcelik G, Steck T, Camara O, Mustea A, Sommer H, Coumbos A, Bogenrieder T, Lichtenegger W, Sehouli J; North-Eastern German Society of Gynecological Oncology Study Group-Ovarian Cancer.

Cancer Chemother Pharmacol. 2008 Aug;62(3):393-400. Epub 2007 Oct 9.

PMID:
17922272
20.

Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).

du Bois A, Pfisterer J, Burchardi N, Loibl S, Huober J, Wimberger P, Burges A, Stähle A, Jackisch C, Kölbl H; Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom; Kommission Uterus.

Gynecol Oncol. 2007 Dec;107(3):518-25. Epub 2007 Oct 25.

PMID:
17910981

Supplemental Content

Support Center